Spots Global Cancer Trial Database for hematopoietic and lymphoid cell neoplasm
Every month we try and update this database with for hematopoietic and lymphoid cell neoplasm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) | NCT04439227 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Adavosertib | 18 Years - | National Cancer Institute (NCI) | |
| Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program | NCT01772771 | Glioma Hematopoietic a... Malignant Solid... Melanoma Sarcoma | Biospecimen Col... Genetic Testing Medical Chart R... | - | M.D. Anderson Cancer Center | |
| Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials | NCT04650178 | COVID-19 Infect... Hematopoietic a... Malignant Solid... Neuropathy | Quality-of-Life... Questionnaire A... | - | M.D. Anderson Cancer Center | |
| Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria) | NCT05178472 | Hematopoietic a... Malignant Solid... Metastatic Mali... | Immunotherapy Stereotactic Ra... Vertebroplasty | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Distress Associated With Coronavirus Disease 2019 and Telehealth on Supportive Care Patients With Advanced Cancer | NCT05058339 | Advanced Malign... COVID-19 Infect... Hematopoietic a... Locally Advance... Metastatic Mali... Recurrent Hemat... Recurrent Malig... | Survey Administ... | 18 Years - | M.D. Anderson Cancer Center | |
| Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) | NCT04439344 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Binimetinib | 18 Years - | National Cancer Institute (NCI) | |
| Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome | NCT04745910 | Hematopoietic a... Malignant Solid... Tumor Lysis Syn... | Pegloticase Rasburicase | 18 Years - | M.D. Anderson Cancer Center | |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) | NCT04439149 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | PI3K-beta Inhib... | 18 Years - | National Cancer Institute (NCI) | |
| A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity | NCT03032783 | Hematopoietic a... | Total-Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate M... Allogeneic Hema... | 18 Years - | Thomas Jefferson University | |
| Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant | NCT04177004 | Allogeneic Hema... Hematopoietic a... | Allogeneic Hema... Cyclophosphamid... Etoposide Fractionated St... Goat Milk Palifermin Sirolimus Tacrolimus | 12 Years - | City of Hope Medical Center | |
| Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer | NCT05403580 | Advanced Malign... Hematopoietic a... | Olanzapine Placebo Adminis... Questionnaire A... | 18 Years - | Mayo Clinic | |
| Survey Assessment of Patient and Provider Impressions of Telemedicine in Radiation Oncology | NCT05496972 | Hematopoietic a... Malignant Solid... | Survey Administ... | 18 Years - | M.D. Anderson Cancer Center | |
| Yoga Intervention for the Improvement of Cancer-Related Stress in Cancer Survivors | NCT04754529 | Hematopoietic a... Malignant Solid... | Quality-of-Life... Survey Administ... Yoga | 18 Years - | Roswell Park Cancer Institute | |
| Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | NCT03816345 | Autoimmune Dise... Crohn Disease Dermatomyositis Hematopoietic a... Inflammatory Bo... Malignant Solid... Multiple Sclero... Psoriasis Psoriatic Arthr... Rheumatoid Arth... Sjogren Syndrom... Systemic Lupus ... Systemic Sclero... Ulcerative Coli... | Biospecimen Col... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) | NCT04439318 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Trametinib Dime... | 18 Years - | National Cancer Institute (NCI) | |
| Thermal Therapy for the Treatment of Depression in Cancer Survivors, the S-WARM Study | NCT04803630 | Hematopoietic a... Malignant Solid... | Quality-of-Life... Questionnaire A... Thermotherapy | 18 Years - | Roswell Park Cancer Institute | |
| Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Chemotherapy | NCT04829539 | Hematopoietic a... Malignant Solid... | Behavioral Inte... Behavioral Inte... Quality-of-Life... Questionnaire A... | 18 Years - | University of Rochester | |
| Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines | NCT02962661 | Cardiomyopathy Heart Failure Hematopoietic a... Malignant Solid... | Best Practice Laboratory Biom... Mesenchymal Ste... Mesenchymal Ste... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Geriatric Assessment Screening Tool for the Identification of At-Risk Older Adults Who Are Undergoing Cancer Treatment | NCT04788758 | Hematopoietic a... Malignant Solid... | Educational Int... Screening Quest... Referral Questionnaire A... | - | Thomas Jefferson University | |
| Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy | NCT03080883 | Cerebral Vein T... Deep Vein Throm... Hematopoietic a... Malignant Solid... Metastatic Mali... Pulmonary Embol... Splanchnic Vein... | Apixaban | 18 Years - | Academic and Community Cancer Research United | |
| Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic | NCT05102656 | COVID-19 Infect... Hematopoietic a... Malignant Solid... | Best Practice Discussion Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| A Multidisciplinary Approach to Improve the Health of Older Adults With Blood Cancers After Stem Cell Transplantation | NCT04914338 | Hematopoietic a... | Health Promotio... Quality-of-Life... Questionnaire A... | 65 Years - | City of Hope Medical Center | |
| Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) | NCT04439240 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas... | FGFR Inhibitor ... | 18 Years - | National Cancer Institute (NCI) | |
| Predicting the Impact of Treatment Toxicities on Health During Cancer ( PATTERN ) | NCT05790538 | Hematopoietic a... Malignant Solid... | Assessment of T... Electronic Heal... Medical Device ... Medical Device ... Survey Administ... | 40 Years - 85 Years | OHSU Knight Cancer Institute | |
| Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | NCT03023631 | Allogeneic Hema... Hematopoietic a... | Recombinant Hum... | 18 Years - | M.D. Anderson Cancer Center | |
| Virtual Reality for the Improvement of Patients Understanding of Disease and Treatment (MRgRT) | NCT05600556 | Hematopoietic a... Malignant Solid... | Magnetic Resona... Computed Tomogr... Best Practice Questionnaire A... Magnetic Resona... Computed Tomogr... Virtual Technol... Questionnaire A... | 18 Years - | Thomas Jefferson University | |
| Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy | NCT02710253 | Hematopoietic a... Metastatic Mali... | External Beam R... Laboratory Biom... Stereotactic Bo... | 18 Years - | M.D. Anderson Cancer Center | |
| Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) | NCT04439344 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Binimetinib | 18 Years - | National Cancer Institute (NCI) | |
| Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer | NCT01902173 | Hematopoietic a... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Mela... Stage IIIC Cuta... Stage IV Cutane... Unresectable Ma... Unresectable Me... | Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Mesy... Magnetic Resona... Trametinib Dime... Uprosertib | 18 Years - | National Cancer Institute (NCI) | |
| Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Chemotherapy | NCT04829539 | Hematopoietic a... Malignant Solid... | Behavioral Inte... Behavioral Inte... Quality-of-Life... Questionnaire A... | 18 Years - | University of Rochester | |
| SARS-CoV-2 Donor-Recipient Immunity Transfer | NCT04666025 | Accelerated Pha... Acute Lymphobla... Acute Myeloid L... Chronic Lymphoc... Chronic Phase C... COVID-19 Infect... Hematopoietic a... Hodgkin Lymphom... Lymphoblastic L... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... | Biospecimen Col... Diagnostic Labo... Electronic Heal... Questionnaire A... | 18 Years - | City of Hope Medical Center | |
| Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease | NCT04198922 | Recurrent Moder... Hematopoietic a... | Acalabrutinib Questionnaire A... | 18 Years - | Fred Hutchinson Cancer Center | |
| Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes | NCT03399773 | Acute Biphenoty... Acute Lymphobla... Chronic Myeloge... Hematopoietic a... Myelodysplastic... Myelodysplastic... | Dilanubicel Cyclophosphamid... Fludarabine Thiotepa Total-Body Irra... Umbilical Cord ... Laboratory Biom... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Multigated Acqu... Electrocardiogr... Computed Tomogr... | 10 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method | NCT05054413 | Hematopoietic a... Malignant Solid... | Questionnaire A... | 21 Years - | M.D. Anderson Cancer Center | |
| Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies | NCT04888338 | Hematopoietic a... | Data Capture Electronic Medi... | 18 Years - | M.D. Anderson Cancer Center | |
| Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers | NCT04459273 | Bladder Carcino... Cervical Carcin... Cholangiocarcin... Hematopoietic a... Hepatocellular ... Malignant Adren... Malignant Brain... Malignant Pleur... Malignant Skin ... Malignant Solid... Malignant Testi... Malignant Thymu... Neuroendocrine ... Thyroid Gland C... Urothelial Carc... Cancer of Unkno... | Computed Tomogr... Gallium Ga 68 F... Positron Emissi... 18F-FDG | 18 Years - | Jonsson Comprehensive Cancer Center | |
| CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant | NCT03922035 | Hematopoietic a... | Best Practice Clostridium but... | 18 Years - | City of Hope Medical Center | |
| Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers | NCT04083170 | Acute Erythroid... Acute Lymphobla... Acute Megakaryo... Acute Myeloid L... Chronic Myeloge... Hematopoietic a... HIV Infection Myelodysplastic... Myelodysplastic... Non-Hodgkin Lym... Refractory Anem... | Fludarabine Cyclophosphamid... Thiotepa Total-Body Irra... Umbilical Cord ... Dilanubicel | 6 Months - 65 Years | Fred Hutchinson Cancer Center | |
| The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study) | NCT05250037 | Bronchiolitis O... Hematopoietic a... | Home spirometry Biospecimen Col... Questionnaire A... | 8 Years - | Fred Hutchinson Cancer Center | |
| CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant | NCT03922035 | Hematopoietic a... | Best Practice Clostridium but... | 18 Years - | City of Hope Medical Center | |
| Testing Counseling and Mobile Health Interventions to Improve Physical Activity and Diet Quality in Survivors of Childhood Cancer | NCT05075759 | Hematopoietic a... Malignant Solid... | Behavioral Inte... Behavioral Inte... Behavioral Inte... Survey Administ... | 18 Years - 54 Years | Fred Hutchinson Cancer Center | |
| Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | NCT05031897 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myelomo... Essential Throm... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloid Leukemi... Myeloid Neoplas... Non-Hodgkin Lym... Plasma Cell Mye... Polycythemia Ve... Small Lymphocyt... | Hematopoietic C... Mycophenolate M... Tacrolimus Cyclophosphamid... Total-Body Irra... Donor Lymphocyt... Fludarabine Melphalan | 18 Years - | Thomas Jefferson University | |
| PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN | NCT04983901 | Hematopoietic a... Malignant Solid... | Imipenem/Cilast... Cefepime Meropenem Piperacillin-Ta... Vancomycin Daptomycin Linezolid | 18 Years - | M.D. Anderson Cancer Center | |
| Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | NCT02706392 | Hematopoietic a... Malignant Solid... Metastatic Lung... Metastatic Trip... Recurrent Acute... Recurrent Mantl... Refractory Chro... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IV Breast... Stage IV Lung N... Unresectable Lu... | Laboratory Biom... ROR1 CAR-specif... | 18 Years - | Fred Hutchinson Cancer Center | |
| Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders | NCT00588991 | Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Chronic Myeloid... Chronic Myelomo... de Novo Myelody... Essential Throm... Hematopoietic a... Myelodysplastic... Polycythemia Ve... Recurrent Adult... Recurrent Adult... Secondary Myelo... | Carboplatin Laboratory Biom... Topotecan Hydro... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion | NCT06184321 | Hematopoietic a... Malignant Solid... | Alteplase Placebo Adminis... | 18 Years - | M.D. Anderson Cancer Center | |
| Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) | NCT04439123 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Capivasertib | 18 Years - | National Cancer Institute (NCI) | |
| Development of the Oncology Opportunity Cost Assessment Tool | NCT04694911 | Hematopoietic a... Malignant Solid... | Focus Group Interview Research or Cli... | 18 Years - | Thomas Jefferson University | |
| 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies | NCT03712878 | Hematopoietic a... | Total-Body Irra... Donor Lymphocyt... Cyclophosphamid... Allogeneic Hema... Tacrolimus Mycophenolate M... | 18 Years - | Thomas Jefferson University | |
| Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology | NCT02847130 | Acute Lymphobla... B-Cell Non-Hodg... Childhood Acute... Childhood Burki... Childhood Neopl... Hematopoietic a... Malignant Solid... Recurrent Child... | Informational I... Interview Medical Chart R... Questionnaire A... | - 20 Years | Children's Oncology Group | |
| Geriatric Assessment Screening Tool for the Identification of At-Risk Older Adults Who Are Undergoing Cancer Treatment | NCT04788758 | Hematopoietic a... Malignant Solid... | Educational Int... Screening Quest... Referral Questionnaire A... | - | Thomas Jefferson University | |
| Whole Body Vibration for the Improvement of Health and Functioning in Participants With Chemotherapy-Induced Peripheral Neuropathy | NCT04170075 | Chemotherapy-In... Hematopoietic a... Malignant Solid... | Whole Body Vibr... | 18 Years - | OHSU Knight Cancer Institute | |
| Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT01251575 | Adult Acute Lym... Adult Acute Mye... Adult Diffuse L... Adult Myelodysp... Adult Non-Hodgk... Aggressive Non-... Childhood Acute... Childhood Acute... Childhood Diffu... Childhood Myelo... Childhood Non-H... Chronic Lymphoc... Chronic Lymphoc... Chronic Phase C... Hematopoietic a... Mantle Cell Lym... Plasma Cell Mye... Prolymphocytic ... Recurrent Chron... Refractory Chro... T-Cell Prolymph... Waldenstrom Mac... Recurrent Diffu... Recurrent Hodgk... | Allogeneic Hema... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra... | - | Fred Hutchinson Cancer Center | |
| Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis | NCT04438382 | Hematopoietic a... Malignant Solid... Steroid-Refract... | Infliximab Intravenous Imm... Prednisone Methylprednisol... | 18 Years - | Eastern Cooperative Oncology Group | |
| Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method | NCT05054413 | Hematopoietic a... Malignant Solid... | Questionnaire A... | 21 Years - | M.D. Anderson Cancer Center | |
| Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization | NCT04439006 | Aplastic Anemia Hematopoietic a... Malignant Solid... Monoclonal B-Ce... Monoclonal Gamm... Myelodysplastic... Symptomatic COV... | Best Practice Ibrutinib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer | NCT05023993 | Hematopoietic a... Malignant Solid... Prediabetes | Exercise Interv... Nicotinamide Ri... | 18 Years - | City of Hope Medical Center | |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) | NCT04439357 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Trametinib Dime... | 18 Years - | National Cancer Institute (NCI) | |
| Yoga Intervention for the Improvement of Cancer-Related Stress in Cancer Survivors | NCT04754529 | Hematopoietic a... Malignant Solid... | Quality-of-Life... Survey Administ... Yoga | 18 Years - | Roswell Park Cancer Institute | |
| Viral Specific T Cell Therapy for COVID-19 Related Pneumonia | NCT04742595 | Hematopoietic a... Malignant Solid... Symptomatic COV... | SARS-CoV-2 Anti... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients | NCT05711667 | Hematopoietic a... Malignant Solid... | Biospecimen Col... Letermovir | 2 Years - 18 Years | Children's Oncology Group | |
| Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study | NCT04593277 | Clinical Stage ... Clinical Stage ... Clinical Stage ... Hematopoietic a... Invasive Malign... Leukemia Lymphoma Malignant Solid... Sarcoma Stage I Colorec... Stage II Colore... Stage III Color... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Thyroid Gland C... | Internet Mobile... Internet-Based ... Questionnaire A... Supportive Care Informational I... | 18 Years - | Fred Hutchinson Cancer Center | |
| Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers | NCT03207854 | Healthy Subject Hematologic and... Hematopoietic a... Immune System D... Malignant Neopl... | Biospecimen Col... Laboratory Biom... Questionnaire A... | 19 Years - | University of Southern California | |
| Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies | NCT04888338 | Hematopoietic a... | Data Capture Electronic Medi... | 18 Years - | M.D. Anderson Cancer Center | |
| 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT03670966 | Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... Recurrent Mixed... Refractory Mixe... Hematopoietic a... | Astatine At 211... Cyclophosphamid... Total-Body Irra... Peripheral Bloo... Bone Marrow Tra... Mycophenolate M... Recombinant Gra... Fludarabine Pho... Tacrolimus Bone Marrow Asp... Biospecimen Col... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain | NCT04296305 | Hematopoietic a... Malignant Solid... | Hydromorphone Placebo Adminis... Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Palliative, Rehabilitation, and Integrated Medicine Handbook for Self Care at Work | NCT05038384 | Hematopoietic a... Malignant Solid... | Survey Administ... | - | M.D. Anderson Cancer Center | |
| Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers | NCT04083170 | Acute Erythroid... Acute Lymphobla... Acute Megakaryo... Acute Myeloid L... Chronic Myeloge... Hematopoietic a... HIV Infection Myelodysplastic... Myelodysplastic... Non-Hodgkin Lym... Refractory Anem... | Fludarabine Cyclophosphamid... Thiotepa Total-Body Irra... Umbilical Cord ... Dilanubicel | 6 Months - 65 Years | Fred Hutchinson Cancer Center | |
| Virtual Reality Experiences for Anxiety and Pain Control | NCT04759183 | Hematopoietic a... Malignant Solid... | Survey Administ... Virtual Reality... Virtual Reality... | 18 Years - 89 Years | OHSU Knight Cancer Institute | |
| Predicting the Impact of Treatment Toxicities on Health During Cancer ( PATTERN ) | NCT05790538 | Hematopoietic a... Malignant Solid... | Assessment of T... Electronic Heal... Medical Device ... Medical Device ... Survey Administ... | 40 Years - 85 Years | OHSU Knight Cancer Institute | |
| Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) | NCT04439175 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Taselisib | 18 Years - | National Cancer Institute (NCI) | |
| Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | NCT05972577 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myeloge... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... Plasma Cell Mye... | Health Promotio... Medical Device ... Quality-of-Life... Questionnaire A... | 60 Years - | Ohio State University Comprehensive Cancer Center | |
| Weighted Blanket Use to Reduce Anxiety in Oncology Patients | NCT06089408 | Hematopoietic a... Malignant Solid... | Best Practice Supportive Care Survey Administ... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) | NCT04439149 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | PI3K-beta Inhib... | 18 Years - | National Cancer Institute (NCI) | |
| Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) | NCT04439331 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult... | Defactinib Hydr... | 18 Years - | National Cancer Institute (NCI) | |
| Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer | NCT05403580 | Advanced Malign... Hematopoietic a... | Olanzapine Placebo Adminis... Questionnaire A... | 18 Years - | Mayo Clinic | |
| Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome | NCT04565665 | COVID-19 Infect... COVID-19-Associ... Hematopoietic a... Malignant Solid... Symptomatic COV... | Best Practice Mesenchymal Ste... | 18 Years - | M.D. Anderson Cancer Center | |
| Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer | NCT03579446 | Hematopoietic a... Malignant Solid... Metastatic Mali... | Hydrocodone Hydromorphone Levorphanol Morphine Oxycodone Oxymorphone Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease | NCT03425526 | Hematopoietic a... Immunocompromis... | Allogeneic Aden... | - | M.D. Anderson Cancer Center | |
| Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study | NCT05053100 | Acute Leukemia Deep Vein Throm... Hematopoietic a... Hodgkin Lymphom... Myeloproliferat... Non-Hodgkin Lym... Plasma Cell Mye... Thrombocytopeni... | Biospecimen Col... Electronic Heal... | 18 Years - | Mayo Clinic |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
